BioSpace News Archive

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2022 financial results on Monday, August 8, 2022, prior to market open.

Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2022 financial results after market close on Wednesday, August 3, 2022.

Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it intends to offer and sell $250 million of American Depositary Shares (“ADSs”), each representing two ordinary shares, in an underwritten public offering.

Tabula Rasa HealthCare, Inc.® (NASDAQ: TRHC), will hold a conference call and webcast to discuss its second quarter 2022 operating results Friday, August 5, 2022 at 8:30 a.m. EDT.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for the second quarter of 2022 on Thursday, August 4, 2022, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after the close of the U.S. financial markets.

Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $164.1 million, or $2.20 per diluted share, during the second quarter of 2022, as compared to $325.0 million, or $3.79 per diluted share, during the second quarter of 2021.

ARUP Laboratories today announced that it has begun in-house testing for monkeypox.

Medpace Holdings, Inc. announced financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Financial Results Revenue for the three months ended June 30, 2022 increased 26.2% to $351.2 million, compared to $278.3 million for the comparable prior-year period.

Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced it has commenced a process to explore and evaluate strategic options to enhance and preserve shareholder value.